Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 6Terminated 3Unknown 2Withdrawn 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Neurofibroma, Plexiform 1Metastatic Solid Tumors. 1Melanoma 1Lymphoma 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Acute 1Hematologic Diseases 1Gastrointestinal Stromal Tumors 1Dermoid Cyst 1Burkitt Lymphoma 1Blast Crisis 1

Interventions

Nivolumab 17Ipilimumab 14pembrolizumab 11Cyclophosphamide 8trametinib 7dabrafenib 6Interleukin-2 6aldesleukin 5Vemurafenib 5Radiotherapy 5sargramostim 4130-nm albumin-bound paclitaxel 4fludarabine 3encorafenib 3binimetinib 3Specimen Handling 3Radiosurgery 3Melphalan 3Granulocyte-Macrophage Colony-Stimulating Factor 3fludarabine phosphate 2Magnetic Resonance Spectroscopy 2Introns 2Infliximab 2Celecoxib 2CTLA-4 Antigen 2Biopsy 2Bevacizumab 2Albumin-Bound Paclitaxel 2yeast-CEA vaccine 1vitespin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Melanoma × Imatinib Mesylate × Clear all
NCT02812693 2018-04-05

Pembrolizumab and Imatinib in Patients With Locally Advanced/Metastatic Melanoma With c-KIT Mutation/Amplification

Ohio State University Comprehensive Cancer Center

Phase 1/2 Withdrawn
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡